{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:12:51Z","timestamp":1780791171985,"version":"3.54.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40256-024-00719-4","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T11:50:33Z","timestamp":1736941833000},"page":"519-532","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Effect of PCSK9 Monoclonal Antibodies on Platelet Reactivity and Cardiovascular Events in Patients Receiving Primary Percutaneous Coronary Intervention: A Propensity Score-Matched Analysis"],"prefix":"10.1007","volume":"25","author":[{"given":"Yao","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qining","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6353-7767","authenticated-orcid":false,"given":"Qianzhou","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"issue":"38","key":"719_CR1","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720\u2013826.","journal-title":"Eur Heart J"},{"issue":"24","key":"719_CR2","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","volume":"64","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):e139\u2013228.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"719_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.recesp.2019.02.019","volume":"73","author":"B \u00c1lvarez \u00c1lvarez","year":"2020","unstructured":"\u00c1lvarez \u00c1lvarez B, AbouJokh Casas C, Cordero A, Mart\u00ednez G\u00f3mez \u00c1, Cid \u00c1lvarez AB, Agra Bermejo R, et al. Early revascularization and long-term mortality in high-risk patients with non-ST-elevation myocardial infarction. The CARDIOCHUS-HUSJ registry. Rev Esp Cardiol (Engl Ed). 2020;73(1):35\u201342.","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"issue":"25","key":"719_CR4","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1016\/j.jacc.2024.04.025","volume":"83","author":"PG Thrane","year":"2024","unstructured":"Thrane PG, Olesen KKW, Thim T, Gyldenkerne C, Hansen MK, St\u00f8dkilde-J\u00f8rgensen N, et al. 10-year mortality after ST-segment elevation myocardial infarction compared to the general population. J Am Coll Cardiol. 2024;83(25):2615\u201325.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"719_CR5","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/ehjcvp\/pvad051","volume":"9","author":"E Ziogos","year":"2023","unstructured":"Ziogos E, Chelko SP, Harb T, Engel M, Vavuranakis MA, Landim-Vieira M, et al. Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: the impact of PCSK9 inhibition. Eur Heart J Cardiovasc Pharmacother. 2023;9(7):636\u201346.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"3","key":"719_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jacl.2018.02.004","volume":"12","author":"G Maulucci","year":"2018","unstructured":"Maulucci G, Cipriani F, Russo D, Casavecchia G, Di Staso C, Di Martino L, et al. Improved endothelial function after short-term therapy with evolocumab. J Clin Lipidol. 2018;12(3):669\u201373.","journal-title":"J Clin Lipidol"},{"issue":"8","key":"719_CR7","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3390\/biomedicines9081073","volume":"9","author":"A Di Minno","year":"2021","unstructured":"Di Minno A, Orsini RC, Chiesa M, Cavalca V, Calcaterra I, Tripaldella M, et al. Treatment with PCSK9 inhibitors in patients with familial hypercholesterolemia lowers plasma levels of platelet-activating factor and its precursors: a combined metabolomic and lipidomic approach. Biomedicines. 2021;9(8):1073.","journal-title":"Biomedicines"},{"key":"719_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.thromres.2020.07.049","volume":"194","author":"A Di Minno","year":"2020","unstructured":"Di Minno A, Gentile M, Iannuzzo G, Calcaterra I, Tripaldella M, Porro B, et al. Endothelial function improvement in patients with familial hypercholesterolemia receiving PCSK-9 inhibitors on top of maximally tolerated lipid lowering therapy. Thromb Res. 2020;194:229\u201336.","journal-title":"Thromb Res"},{"issue":"34","key":"719_CR9","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"},{"issue":"25","key":"719_CR10","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082\u2013143.","journal-title":"Circulation"},{"issue":"15","key":"719_CR11","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1001\/jama.2021.0716","volume":"325","author":"H Kamran","year":"2021","unstructured":"Kamran H, Jneid H, Kayani WT, Virani SS, Levine GN, Nambi V, et al. Oral antiplatelet therapy after acute coronary syndrome: a review. JAMA. 2021;325(15):1545\u201355.","journal-title":"JAMA"},{"issue":"6","key":"719_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1055\/a-2156-7872","volume":"124","author":"Y Ueki","year":"2024","unstructured":"Ueki Y, H\u00e4ner JD, Losdat S, Gargiulo G, Shibutani H, B\u00e4r S, et al. Effect of alirocumab added to high-intensity statin on platelet reactivity and noncoding RNAs in patients with AMI: a substudy of the PACMAN-AMI trial. Thromb Haemost. 2024;124(6):517\u201327.","journal-title":"Thromb Haemost"},{"issue":"10","key":"719_CR13","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.111.029165","volume":"124","author":"MJ Price","year":"2011","unstructured":"Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation. 2011;124(10):1132\u20137.","journal-title":"Circulation"},{"issue":"2","key":"719_CR14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41401-019-0278-9","volume":"41","author":"HY Wu","year":"2020","unstructured":"Wu HY, Zhang C, Zhao X, Qian JY, Wang QB, Ge JB. Residual platelet reactivity is preferred over platelet inhibition rate in monitoring antiplatelet efficacy: insights using thrombelastography. Acta Pharmacol Sin. 2020;41(2):192\u20137.","journal-title":"Acta Pharmacol Sin"},{"issue":"9","key":"719_CR15","doi-asserted-by":"publisher","first-page":"621","DOI":"10.26599\/1671-5411.2023.09.008","volume":"20","author":"JJ Li","year":"2023","unstructured":"Li JJ, Zhao SP, Zhao D, Lu GP, Peng DQ, Liu J, et al. 2023 China guidelines for lipid management. J Geriatr Cardiol. 2023;20(9):621\u201363.","journal-title":"J Geriatr Cardiol"},{"issue":"2","key":"719_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","volume":"9","author":"TA Jacobson","year":"2015","unstructured":"Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1\u2013full report. J Clin Lipidol. 2015;9(2):129\u201369.","journal-title":"J Clin Lipidol"},{"issue":"17","key":"719_CR17","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","volume":"34","author":"H-TC Group","year":"2013","unstructured":"Group H-TC. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279\u201391.","journal-title":"Eur Heart J"},{"issue":"19","key":"719_CR18","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","volume":"294","author":"TR Pedersen","year":"2005","unstructured":"Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437\u201345.","journal-title":"JAMA"},{"issue":"1","key":"719_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jacl.2019.10.015","volume":"14","author":"Y Han","year":"2020","unstructured":"Han Y, Chen J, Chopra VK, Zhang S, Su G, Ma C, et al. ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand. J Clin Lipidol. 2020;14(1):98-108.e8.","journal-title":"J Clin Lipidol"},{"issue":"24","key":"719_CR20","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","volume":"62","author":"US Tantry","year":"2013","unstructured":"Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62(24):2261\u201373.","journal-title":"J Am Coll Cardiol"},{"key":"719_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.atherosclerosis.2016.03.010","volume":"248","author":"JM Cheng","year":"2016","unstructured":"Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, Boersma E, van Geuns RJ, Serruys PW, et al. PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study. Atherosclerosis. 2016;248:117\u201322.","journal-title":"Atherosclerosis"},{"issue":"1","key":"719_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/path.4630","volume":"238","author":"I Giunzioni","year":"2016","unstructured":"Giunzioni I, Tavori H, Covarrubias R, Major AS, Ding L, Zhang Y, et al. Local effects of human PCSK9 on the atherosclerotic lesion. J Pathol. 2016;238(1):52\u201362.","journal-title":"J Pathol"},{"issue":"5","key":"719_CR23","doi-asserted-by":"publisher","first-page":"462","DOI":"10.5551\/jat.RV17003","volume":"24","author":"MD Shapiro","year":"2017","unstructured":"Shapiro MD, Fazio S. PCSK9 and atherosclerosis - lipids and beyond. J Atheroscler Thromb. 2017;24(5):462\u201372.","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"719_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12933-020-01142-0","volume":"19","author":"J Peng","year":"2020","unstructured":"Peng J, Liu MM, Jin JL, Cao YX, Guo YL, Wu NQ, et al. Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study. Cardiovasc Diabetol. 2020;19(1):167.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"719_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12933-022-01519-3","volume":"21","author":"L Song","year":"2022","unstructured":"Song L, Zhao X, Chen R, Li J, Zhou J, Liu C, et al. Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes. Cardiovasc Diabetol. 2022;21(1):80.","journal-title":"Cardiovasc Diabetol"},{"key":"719_CR26","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.ijcard.2016.10.084","volume":"227","author":"EP Navarese","year":"2017","unstructured":"Navarese EP, Kolodziejczak M, Winter MP, Alimohammadi A, Lang IM, Buffon A, et al. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: the PCSK9-REACT study. Int J Cardiol. 2017;227:644\u20139.","journal-title":"Int J Cardiol"},{"issue":"1","key":"719_CR27","first-page":"996","volume":"9","author":"Y Yao","year":"2024","unstructured":"Yao Y, Qiu Q, Li X, Wang Z, Xu S, Lv Q. Clinical significance of PCSK9 and soluble P-selectin in predicting major adverse cardiovascular events after primary percutaneous coronary intervention in patients with acute coronary syndrome. Cardiovasc Innov Appl. 2024;9(1):996.","journal-title":"Cardiovasc Innov Appl"},{"issue":"13","key":"719_CR28","doi-asserted-by":"publisher","first-page":"7193","DOI":"10.3390\/ijms22137193","volume":"22","author":"V Cammisotto","year":"2021","unstructured":"Cammisotto V, Baratta F, Castellani V, Bartimoccia S, Nocella C, D\u2019Erasmo L, et al. Proprotein convertase subtilisin kexin type 9 inhibitors reduce platelet activation modulating ox-LDL pathways. Int J Mol Sci. 2021;22(13):7193.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"719_CR29","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.numecd.2019.09.012","volume":"30","author":"C Barale","year":"2020","unstructured":"Barale C, Bonomo K, Frascaroli C, Morotti A, Guerrasio A, Cavalot F, et al. Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: a 12-month follow-up. Nutr Metab Cardiovasc Dis. 2020;30(2):282\u201391.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"16","key":"719_CR30","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.119.041998","volume":"140","author":"NA Marston","year":"2019","unstructured":"Marston NA, Giugliano RP, Im K, Silverman MG, O\u2019Donoghue ML, Wiviott SD, et al. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. Circulation. 2019;140(16):1308\u201317.","journal-title":"Circulation"},{"issue":"4","key":"719_CR31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jacc.2018.10.039","volume":"73","author":"M Szarek","year":"2019","unstructured":"Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, et al. alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2019;73(4):387\u201396.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"719_CR32","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jamacardio.2019.0886","volume":"4","author":"SA Murphy","year":"2019","unstructured":"Murphy SA, Pedersen TR, Gaciong ZA, Ceska R, Ezhov MV, Connolly DL, et al. Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER trial. JAMA Cardiol. 2019;4(7):613\u20139.","journal-title":"JAMA Cardiol."},{"issue":"2","key":"719_CR33","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40200-020-00557-6","volume":"19","author":"A Cordero","year":"2020","unstructured":"Cordero A, Rodr\u00edguez-Ma\u00f1ero M, F\u00e1cila L, Fern\u00e1ndez-Olmo MR, G\u00f3mez-Mart\u00ednez MJ, Valle A, et al. Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials. J Diabetes Metab Disord. 2020;19(2):759\u201365.","journal-title":"J Diabetes Metab Disord"},{"issue":"1","key":"719_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12872-020-01827-0","volume":"21","author":"T Li","year":"2021","unstructured":"Li T, Zhang Y, Cong H. Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes. BMC Cardiovasc Disord. 2021;21(1):19.","journal-title":"BMC Cardiovasc Disord"},{"issue":"11","key":"719_CR35","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/clc.22583","volume":"39","author":"J Abtan","year":"2016","unstructured":"Abtan J, Bhatt DL, Elbez Y, Sorbets E, Eagle K, Ikeda Y, et al. Residual ischemic risk and its determinants in patients with previous myocardial infarction and without prior stroke or TIA: insights from the REACH Registry. Clin Cardiol. 2016;39(11):670\u20137.","journal-title":"Clin Cardiol"},{"issue":"15","key":"719_CR36","first-page":"1254","volume":"18","author":"F Franchi","year":"2023","unstructured":"Franchi F, Ortega-Paz L, Rollini F, Been L, Rivas A, Maaliki N, et al. Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study. EuroIntervention. 2023;18(15):1254\u201365.","journal-title":"EuroIntervention"},{"issue":"4","key":"719_CR37","first-page":"282","volume":"13","author":"DD Li","year":"2016","unstructured":"Li DD, Wang XY, Xi SZ, Liu J, Qin LA, Jing J, et al. Relationship between ADP-induced platelet-fibrin clot strength and anti-platelet responsiveness in ticagrelor treated ACS patients. J Geriatr Cardiol. 2016;13(4):282\u20139.","journal-title":"J Geriatr Cardiol"},{"issue":"37","key":"719_CR38","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000034974","volume":"102","author":"ST Gao","year":"2023","unstructured":"Gao ST, Wang Y, Ma L. Effect of ticagrelor and clopidogrel dual antiplatelet therapy on MPVLR, MAADP, and AA inhibition rate in acute coronary syndrome patients after percutaneous coronary intervention. Medicine (Baltimore). 2023;102(37): e34974.","journal-title":"Medicine (Baltimore)"},{"issue":"20","key":"719_CR39","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","volume":"74","author":"KC Koskinas","year":"2019","unstructured":"Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, et al. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS). J Am Coll Cardiol. 2019;74(20):2452\u201362.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"719_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022348","volume":"8","author":"YX Cao","year":"2018","unstructured":"Cao YX, Li S, Liu HH, Li JJ. Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2018;8(9): e022348.","journal-title":"BMJ Open"},{"issue":"12","key":"719_CR41","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1016\/j.jcmg.2019.06.022","volume":"12","author":"RM Hoogeveen","year":"2019","unstructured":"Hoogeveen RM, Opstal TSJ, Kaiser Y, Stiekema LCA, Kroon J, Knol RJJ, et al. PCSK9 antibody alirocumab attenuates arterial wall inflammation without changes in circulating inflammatory markers. JACC Cardiovasc Imaging. 2019;12(12):2571\u20133.","journal-title":"JACC Cardiovasc Imaging"},{"key":"719_CR42","doi-asserted-by":"publisher","first-page":"1138787","DOI":"10.3389\/fcvm.2023.1138787","volume":"10","author":"H Chen","year":"2023","unstructured":"Chen H, Chen X. PCSK9 inhibitors for acute coronary syndrome: the era of early implementation. Front Cardiovasc Med. 2023;10:1138787.","journal-title":"Front Cardiovasc Med."},{"issue":"18","key":"719_CR43","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"719_CR44","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"18","key":"719_CR45","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","volume":"327","author":"L R\u00e4ber","year":"2022","unstructured":"R\u00e4ber L, Ueki Y, Otsuka T, Losdat S, H\u00e4ner JD, Lonborg J, et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022;327(18):1771\u201381.","journal-title":"JAMA"},{"issue":"12","key":"719_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0295359","volume":"18","author":"TF Imran","year":"2023","unstructured":"Imran TF, Khan AA, Has P, Jacobson A, Bogin S, Khalid M, et al. Proprotein convertase subtilisn\/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: a systematic review and meta-analysis. PLoS\u00a0One. 2023;18(12): e0295359.","journal-title":"PLoS\u00a0One"},{"issue":"25","key":"719_CR47","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","volume":"109","author":"S Matetzky","year":"2004","unstructured":"Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109(25):3171\u20135.","journal-title":"Circulation"},{"issue":"10","key":"719_CR48","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/phar.1477","volume":"34","author":"PP Dobesh","year":"2014","unstructured":"Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy. 2014;34(10):1077\u201390.","journal-title":"Pharmacotherapy"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00719-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00719-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00719-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T08:03:01Z","timestamp":1751702581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00719-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["719"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00719-4","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"17 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated and\/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Yao Yao, Qining Qiu, Zi Wang, Shikun Xu, and Qianzhou Lv declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No external funding was used in the preparation of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Conceptualization: Qianzhou Lv and Yao Yao. Methodology: Yao Yao and Zi Wang. Software: Yao Yao and Qining Qiu. Validation: Qianzhou Lv, Shikun Xu, Yao Yao, and Qining Qiu. Formal analysis: Yao Yao and Qining Qiu. Investigation: Yao Yao and Zi Wang. Resources: Shikun Xu. Data curation: Yao Yao and Qining Qiu. Writing \u2013 original draft preparation: Yao Yao. Writing \u2013 review and editing: Qining Qiu and Shikun Xu. Visualization: Qianzhou Lv and Shikun Xu. Supervision: Shikun Xu. Project administration: Qianzhou Lv.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The ethics committee at Zhongshan Hospital, Fudan University, China, sanctioned the research, adhering to the principles of the Declaration of Helsinki.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided informed consent before enrollment.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}